Diseases such as hypertension, atherosclerosis, hyperlipidemia, and diabetes are associated with vascular, functional and structural changes including endothelial dysfunction, altered contractility and vascular remodeling. The role of vascular endothelium in modulating vascular tone and maintaining cardiovascular homeostasis in blood vessels, through the production of an array of both relaxant (e.g., nitric oxide [NO], prostacyclin) and constrictor factors (such as thromboxane, endothelin), has been widely reported.
was indirectly measured using a tail-cuff apparatus (BP-98, Softron) which was controlled with a personal computer. Values are presented as the average of three separate measurements.
Measurement of Blood Cell Counts and Plasma Fibrinogen Blood from the heart of each sacrificed SHR was separately collected into heparinized syringes containing 5% heparin and 2% sodium citrate, and was instantly and gently mixed. A small portion of the blood was used for the cell counts which were determined by a cell counter (Celltac a, Nihon Kohden, Tokyo). Plasma was immediately separated from the other portion of the blood by centrifugation at 3000 g for 15 min (Kubota 8700, Kubota, Tokyo). The measurement of plasma fibrinogen was performed at the Special Reference Laboratories (SRL) (Tokyo).
Vascular Reactivity Experiments The experiments were conducted as previously described by Goto et al. 12) Briefly, ASX-O-and olive oil-treated SHR (?, 14-16 weeks age, 254-320 g body weight) were anesthetized (50 mg/kg i.p. pentobarbital) and sacrificed by cutting the abdominal aorta. Aortic rings (3 mm) were prepared from the thoracic aorta, mounted on steel hooks in a Magnus chamber (Kishimoto UC-5TD, Kyoto, Japan) and attached to a force-displacement transducer (Kishimoto UM-203, Kyoto) and a recorder (Niko Bioscience T-634, Tokyo). Baths were filled with Krebs solution maintained at 37°C and bubbled continuously with 5% CO 2 in O 2 at a pH of 7.4. The rings were equilibrated for 40 min at an initial resting tension of 1 g, and then contracted with 6ϫ10 Ϫ2 M potassium chloride (KCl) to determine the optimal resting tension. When the contraction reached a steady maximal response, 10 Ϫ6 M acetylcholine (ACh) was added to confirm the status of the endothelium. ACh induced relaxation in rings with intact endothelium, whereas the relaxation disappeared in the denuded ones. The Krebs solution was then replaced and the experiments were carried out.
Contractile Responses In a series of experiments, each of the rings was pretreated with 10 Ϫ4 M N G -nitro-L-arginine methyl ester (L-NAME) for 60 min and then tested agonists were added, separately. In one experiment, 10 Ϫ4 M xanthine was added for 5 min followed by 10 mU/ml xanthine oxidase (XOD). In two other sets, angiotensin II (Ang II) was added at 10 Ϫ7 M and 10 Ϫ6 M, separately. The contraction was calculated as a percentage of the corresponding contraction induced by 6ϫ10 Ϫ2 M KCl. Relaxant Responses In another series of experiments, each of the rings was contracted by treatment with 5ϫ10 Ϫ7 M phenylephrine (Phe). When the contraction reached a plateau, ACh was added at concentrations ranging from 10 Ϫ9 to 10 Ϫ4 M, cumulatively. In another set, similar cumulative concentrations of sodium nitroprusside (SNP) were added. The relaxation was expressed as a percentage of the decrease in the maximal tension contracted with 5ϫ10 Ϫ7 M Phe. Microchannel Array Flow Analysis The transit time of a whole blood through the microchannel array was measured and used as a marker index of blood fluidity. The detailed procedures and apparatus of the microchannel analysis (Microchannel Flow Analyzer [MC-FAN] type KH-2, Hitachi Haramachi Electronics Co., Ltd., Hitachi, Tokyo) were described previously. 13, 14) Briefly, microgrooves formed on the surface of a single crystal silicon substrate were converted to leak-proof microchannels by covering them tightly with an optical flat glass plate. The microgrooves in the silicon microchannel chip (Bloody-6-5, 8736 channels; width, 5 mm; depth, 4.5 mm; length, 20 mm -Hitachi Haramachi Electronics Co., Ltd.) were pre-filled with saline. The heparinized whole blood samples were forced to flow through the microchannels under a pressure difference of 20 cm H 2 O. To assess the filterability of the whole blood, the transit time for each 20, 40, 60, 80 and 100 ml of blood was determined. These measurements were performed immediately after blood sampling at a room temperature between 20 and 25°C. The MC-FAN was calibrated with the saline before each new measurement. The blood passage through an individual channel was observed and recorded using a video microscope system (WAT-231S, WATEC, Tokyo).
Statistical Analysis Statistical significance was determined by the Student's t-test for unpaired observations and Mann-Whitney Rank Sum Test. One-way Analysis of Variance (ANOVA) was performed for multiple comparisons between the groups. Differences with pϽ0.05 were considered statistically significant.
Drugs and Chemicals All the reagents used in these experiments were of analytical grades. Xanthine, XOD, L-NAME, ACh, Phe, SNP, KCl and Krebs solution reagents were obtained from Wako (Wako Pure Chemicals, Tokyo). Other materials were purchased as follows: pentobarbital sodium from Tokyo Chemical Industry (TCI) (Tokyo Kasei, Tokyo), heparin from Mochida (Novo-Heparin, Mochida, Tokyo), sodium citrate from Fuso (Fuso, Osaka) and Ang II from Calbiochem (Calbiochem, CA, U.S.A).
RESULTS

Effects of ASX-O on the BP
In this study, ASX-O showed significant BP-lowering effects on the arterial BP, as represented by the effect on the mean blood pressure (MBP) (pϽ0.05) (Fig. 1 ) and summarized in Table 1 . Throughout the 7 weeks treatment period, the daily administered ASX-O showed no significant or consistent effect on the HR, however, a decrease in the HR was exhibited on week 7. The body weight (BW) of ASX-O-treated SHR was not changed compared to the control group.
Blood Cell Counts and Plasma Fibrinogen ASX (5 mg/kg) neither changed the blood cell count indices nor did it cause a significant change in the plasma fibrinogen level compared to the control (Table 2) . Vascular Reactivity of ASX-O on Rat Aorta, ex Vivo 1) Effects on Contraction Induced by the Xanthine/XOD System: The xanthine/XOD-induced contraction of the aortic preparations was significantly reduced in the ASX-O-treated SHR compared to the olive oil-treated ones (pϽ0.05) (Fig.  2) .
2) Contractile Responses to Phe and Ang II: ASX-O demonstrated a significant reduction of the contractile responses of the aortic preparations to Phe (at 5ϫ10 Ϫ7 M) (pϽ0.05) (Fig. 3) and the responses to Ang II (10 Ϫ7 M) (pϽ0.001) (Fig. 4) , compared to the vehicle control.
3) Vasorelaxant Responses to SNP and ACh: The vasorelaxant response to SNP (at 10 Ϫ9 -10 Ϫ8 M) was significant in the ASX-O-treated group compared to the control group (Fig. 5) . However, the response to ACh was not significant (Fig. 6) .
Microchannel Array Flow Analysis The effects of ASX-O on the blood fluidity were evaluated by the microchannel transit time of the whole blood, measured by the MC-FAN. The transit time of the blood was significantly decreased in the ASX-O-treated SHR compared to the control (pϽ0.05) (Fig. 7) .
DISCUSSION
We previously reported the BP lowering effects of astaxanthin (ASX-O) in SHR. In the current study, in order to verify the antihypertensive mechanisms of action of this substance, we studied the effects of its oral administration in the SHR on vascular reactivity. We investigated these effects using a systematic approach in order to determine both contractile and relaxant responses of the aortic preparations. We found that ASX (at the dose of 5 mg/kg/d for 7 weeks) had no significant effect on ACh-induced relaxation, which is an endothelium-dependent relaxation. This result implies that the endothelial-derived NO production and/or release might not be significantly altered by ASX at the given dose in the SHR. However, in this study ASX-O showed significant enhancement of the endothelium-independent SNP-induced relaxation which is reflective of an increase in cyclic nucleotides that in turn, decrease intracellular calcium and myofilament Ca 2ϩ sensitivity. 15) On the other hand, the constrictive effects by Phe and Ang II tend to be significantly ameliorated by ASX-O (pϽ0.05). We focused on determining the responses to the [alpha] 1 -selective agonist, Phe. ASX-O significantly ameliorated the Phe-induced contraction of the aortic rings. Hence it can be postulated that the administration of ASX-O may improve the cardiovascular functions in the SHR by normalization of the sensitivity of the adrenoceptor sympathetic pathway, particularly the [alpha]-adrenoceptors.
The vasoconstrictor Ang II had been reported to increase the nicotinamide adenine dinucleotide phosphate (NADPH)/ NADPH oxidase activity and the superoxide anion ( · O 2 Ϫ ) production in cultured vascular smooth muscle cells in vitro. 16) Those findings were consistent with the observation of the increased vascular · O 2 Ϫ concentrations in rats that became hypertensive as a result of chronic infusion with Ang II in vivo. 17) Interestingly, a down-regulation of the expression of the NADPH oxidase subunits and a lowering of the · O 2 Ϫ level in endothelial cells by some polyphenols had been reported by Ying et al. 18) ASX is well known to have a potential antioxidant activity, and the present findings, together with those reported earlier, may urge us to consider the link between the vascular effects of ASX-O and Ang II-induced ROS-production. ASX-O, in this study, has reduced the contractile response to Ang II in the SHR aortic preparations. This effect was evident in the presence of an intact endothelium and the NO synthase inhibitor L-NAME. However, it is necessary to investigate the effect in endothelium-denuded preparations and without L-NAME. Furthermore, the vascular contraction induced by the Xan/XOD system was significantly reduced by the ASX-O treatment. This contraction is presumably induced by the oxygen-derived free radicals produced by the system. Although the inhibitory effect by the ASX-O can be explained, in part, by its scavenging activity, further investigations may be necessary.
In the microcirculation, the hemorheological factors have been implicated to play an important role in the pathogenesis of different cardiovascular diseases. 19) Moreover, the BP has been positively associated with plasma viscosity, for which fibrinogen is considered to be the main determinant factor. 20) In natural medicines, some substances have been reported to have significant effects on the erythrocyte deformability and/or blood viscosity, on the fibrinogen concentration and on blood rheology in rats. 21, 22) The microchannel (MC-FAN) has been reported as a useful tool in analyzing blood rheology in pathophysiological conditions 14) and to evaluate the effects of substances on the blood flow rate and fluidity. 13, 14, 23) In the current study, ASX-O significantly decreased the microchannel transit time of the whole blood compared to the vehicle control (pϽ0.05), without affecting the blood cell counts. This suggests that ASX-O may act in modulating the blood fluidity in hypertension. This improvement of the hemorheology by ASX-O may not be related to the plasma fibrinogen level which was not significantly changed in the present experiment (Table 2) . Thus this improvement is probably due to modulatory effects on the deformability or aggregation of the blood cells and/or by effects on the blood viscosity, however, further study may be needed to verify these effects.
In general, the beneficial roles of some natural antioxidants against some cardiovascular diseases have been reported, 24, 25) and several studies, both in animal models and human subjects, have reported improvements of the blood vessel function by dietary antioxidants and vitamin supplementation. 26, 27) Most recently, an ASX derivative was reported to have cardioprotection and myocardial salvage potentials in a rat infarct model. 28) Nevertheless, our present findings implicate ASX as a potential candidate in extending the vascular protective actions and in improving the blood fluidity in hypertension.
